Dr. Weitzman brings to Biosion over 20 years of Oncology clinical development experience in the biotech and pharmaceutical industries. 

Before joining Biosion, Dr. Weitzman established his own consulting company over 6 years and focused on early oncology drug development. Prior to establishing his consulting company, Dr. Weitzman worked with Exelixis where he served as Vice President of Clinical Development where he oversaw the development of cabozantinib spanning the period from its initial phase I study to subsequent approvals. Prior to Exelixis, he was Group Director at Genentech overseeing Avastin’s development in NSCLC and GBM. He has also previously worked at Novartis  and Eli Lilly.

Dr. Weitzman holds an M.D. degree from The University of Western Ontario and completed an internal medicine residency at The Mount Sinai Hospital in NYC and a medical oncology fellowship at Columbia Presbyterian Medical Center.